Previous 10 | Next 10 |
3 Ways to Make Income With Penny Stocks in 2023 Trading penny stocks has the potential to provide you with a full-time income, but it’s important to approach it with caution and knowledge. Penny stocks , which are defined as stocks that trade for less than $5 per share, can offer i...
BRYAN, Texas, Jan. 05, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 11,545,238...
BRYAN, Texas, Dec. 09, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced the closing of its previously announced underwritten public offering of an aggregate of 3,3...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips 2022 was a terrible year for the stock market. Fortunately for 2023, news of lower interest rate hikes hints at a new bull market. However, with this renewed vigor, investors should look at which companies they should offload...
iBio ( NYSE: IBIO ) shares down 37.6% after-hours after the firm has priced its previously announced underwritten public offering of an aggregate of 3,365,385 shares of its common stock, Series A warrants to purchase up to 3,365,385 shares of common stock and Series B warrants...
BRYAN, Texas, Dec. 06, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced the pricing of its previously announced underwritten public offering of an aggregate of 3,3...
Immunotherapies company iBio ( NYSE: IBIO ) intends to offer and sell shares and series A and series B warrants in an underwritten public offering. The company also intends to grant underwriter a 30-day option to purchase additional shares and/or purchase warrants at the public offeri...
BRYAN, Texas, Dec. 06, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced it intends to offer and sell, subject to market and other conditions, shares of its common ...
BRYAN, Texas, Dec. 06, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announced today that its Chief Scientific Officer, Martin Brenner, DVM, Ph.D., will participate in a vir...
BRYAN, Texas, Dec. 05, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announced today it will present two posters at the Antibody Engineering & Therapeutics Conference ...
News, Short Squeeze, Breakout and More Instantly...
– The sale of the facility eliminates $13.2M of secured debt – – Completes iBio’s transition to an AI and precision biologics innovation company - SAN DIEGO, June 03, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or th...
2024-05-28 07:30:05 ET Chardan Capital analyst issues BUY recommendation for IBIO on May 28, 2024 05:34AM ET. IBIO was trading at $2.19 at issue of the analyst recommendation. The overall analyst consensus : HOLD. Current analyst recommendations are : 1 - Hold recommenda...
Strengthened cash position with investment by healthcare specialist investors Expanding into cardio-metabolic space through AstralBio collaboration BRYAN, Texas and SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company...